Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Carr
Brian I
BI
Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. brian.carr@kimmelcancercenter.org
Carroll
Stuart
S
Muszbek
Noemi
N
Gondek
Kathleen
K
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000191:economics* / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D003362:Cost-Benefit Analysis; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D008390:Markov Chains; D018803:Models, Economic; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib; D016019:Survival Analysis
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib